Zhi Xiang Jintai (688443.SH) has received approval for the clinical trial application of the research product GR2301 injection.
Zhixiang Kintai (688443.SH) announcement, the company has received approval from the National Medical Products Administration for the issuance of the "Clinical Trial of Drugs...".
Zhixiang Jintai (688443.SH) announced that the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's clinical trial application for GR2301 injection has been approved. The announcement shows that GR2301 injection is a recombinant humanized anti-IL-15 monoclonal antibody independently developed by the company, which can block the binding of IL-15 to IL-15R and IL-15 & IL-15R complex to IL-2R & IL-2R complex, inhibit the downstream JAK-STAT signaling pathway, and achieve the therapeutic effect of treating autoimmune diseases such as vitiligo caused by IL-15 expression imbalance.
Related Articles
Shenzhen SDG Service (300917.SZ) shareholder Yin Kun Company plans to reduce its shareholding by no more than 2%.
DongGuan YuTong Optical Technology (300790.SZ) plans to collectively reduce their holdings by up to 2.3 million shares.
Guangdong Lvtong New Energy Electric Vehicle Technology (301322.SZ) and GEM Co., Ltd. subsidiary Power Regeneration have signed a strategic cooperation framework agreement.
Shenzhen SDG Service (300917.SZ) shareholder Yin Kun Company plans to reduce its shareholding by no more than 2%.
DongGuan YuTong Optical Technology (300790.SZ) plans to collectively reduce their holdings by up to 2.3 million shares.
Guangdong Lvtong New Energy Electric Vehicle Technology (301322.SZ) and GEM Co., Ltd. subsidiary Power Regeneration have signed a strategic cooperation framework agreement.
